Tom 8, Nr 1 (2023)
Praca badawcza (oryginalna)
Opublikowany online: 2022-12-19

dostęp otwarty

Wyświetlenia strony 2518
Wyświetlenia/pobrania artykułu 135
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Morbidity and mortality trends of the most common cancers in 1990–2019. Poland’s position compared to other European countries

Marta J. Miklewska12, Klaudia Barańska13, Urszula Wojciechowska1, Urszula Sulkowska1, Jerzy E. Tyczyński1, Joanna A. Didkowska14
Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2023;8(1):46-55.


Introduction. The purpose of the study was to evaluate the trends in morbidity and mortality of the selected cancer sites in Poland against other European countries.

Material and methods. Countries for analysis were selected based on geographical location. Estimates of age-adjusted incidence and mortality rates were calculated using the new European 2013 standard population. Lung, colorectal, breast, and prostate cancers were chosen. Time trends for age-standardized rates were analyzed using Joinpoint Re­gression software.

Results. Poland differed from other analyzed countries mainly in terms of cancer mortality. Poland is a country with one of the smallest amounts of current expenditures on health care per capita, which translates into one of the highest levels of cancer mortality in both women and men.

Conclusions. Compared to other countries, Poland’s cancer outcomes on population level are unsatisfactory. The si­tuation may improve with the introduction of educational and screening programs.

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF


  1. Sheiman I, Shishkin S, Shevsky V. The evolving Semashko model of primary health care: the case of the Russian Federation. Risk Manag Healthc Policy. 2018; 11: 209–220.
  2. Puchta P. Polish Healthcare System in Transition - Perceptions of the OLD and NEW Systems n.d.:67.
  3. Sagan A, Panteli D, Borkowski W, et al. Europe WHORO for, Policies EO on HS. Poland: health system review. 2011.
  4. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
  5. Cancer statistics - specific cancers. n.d. (25.10.2022).
  6. Didkowska J, Wojciechowska U, Michalek IM, et al. Cancer incidence and mortality in Poland in 2019. Sci Rep. 2022; 12(1): 10875.
  7. Raporty | KRN n.d. (25.10.2022).
  8. Główny Urząd Statystyczny. n.d. (25.10.2022).
  9. Startseite - STATISTIK AUSTRIA - Die Informationsmanager. n.d. (25.10.2022).
  10. SVOD. n.d. (25.10.2022).
  11. Nordcan 2.0. n.d. (25.10.2022).
  12. PxWeb - Select table. n.d. (25.10.2022).
  13. WHO cancer mortality database (IARC). n.d. (25.10.2022).
  14. European Cancer Information System. n.d. (25.10.2022).
  15. National Health Information Center. n.d. (25.10.2022).
  16. Cancer Registries. n.d. (25.10.2022).
  17. European Commission, Eurostat. Revision of the European Standard Population: report of Eurostat’s task force: 2013 edition. LU: Publications Office 2013.
  18. Kim HJ, Fay M, Feuer E, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2001; 19(3): 335–351, doi: 10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>;2-z.
  19. Hitiris T, Posnett J. The determinants and effects of health expenditure in developed countries. J Health Econ. 1992; 11(2): 173–181.
  20. File:Current healthcare expenditure, 2019.png. n.d.,_2019.png (18.11.2022).
  21. Cancer Prevention Overview (PDQ®)–Patient Version - NCI. 2009. (18.11.2022).
  22. Parkin DM, Boyd L, Walker LC. 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer. 2011; 105 Suppl 2(Suppl 2): S77–S81.
  23. Danaei G, Hoorn SV, Lopez A, et al. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005; 366(9499): 1784–1793.
  24. European Code Against Cancer - About the code. n.d. (18.11.2022).
  25. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000; 321(7257): 323–329.
  26. Didkowska J, Wojciechowska U, Mańczuk M, et al. Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med. 2016; 4(8): 150.
  27. Graham H. Smoking prevalence among women in the European Community 1950–1990. Social Science & Medicine. 1996; 43(2): 243–254.
  28. Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol. 2017; 18(12): e754–e766.
  29. Merriel SWD, Pocock L, Gilbert E, et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 2022; 20(1): 54.
  30. Carr PR, Weigl K, Jansen L, et al. Healthy Lifestyle Factors Associated With Lower Risk of Colorectal Cancer Irrespective of Genetic Risk. Gastroenterology. 2018; 155(6): 1805–1815.e5.
  31. Botteri E, Peveri G, Berstad P, et al. Changes in Lifestyle and Risk of Colorectal Cancer in the European Prospective Investigation Into Cancer and Nutrition. Am J Gastroenterol. 2022 [Epub ahead of print].
  32. Cancer Screening in the European Union (2017).pdf n.d.
  33. Healthcare activities statistics - preventive services. n.d. (15.11.2022).
  34. Coleman C. Early Detection and Screening for Breast Cancer. Semin Oncol Nurs. 2017; 33(2): 141–155.
  35. Patasius A, Krilaviciute A, Smailyte G. Prostate Cancer Screening with PSA: Ten Years' Experience of Population Based Early Prostate Cancer Detection Programme in Lithuania. J Clin Med. 2020; 9(12).
  36. Innos K, Lang K, Pärna K, et al. Age-specific cancer survival in Estonia: recent trends and data quality. Clin Epidemiol. 2015; 7: 355–362.
  37. Vutuc C, Schernhammer ES, Haidinger G, et al. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Wien Klin Wochenschr. 2005; 117(13-14): 457–461.
  38. Kjellman A, Akre O, Norming U, et al. 15-year followup of a population based prostate cancer screening study. J Urol. 2009; 181(4): 1615–21; discussion 1621.
  39. Ondrusova M, Ondrus D, Karabinos J, et al. Trends in prostate cancer incidence and mortality before and after the introduction of PSA testing in the Slovak and Czech Republics. Tumori. 2011; 97(2): 149–155.
  40. Outzen M, Brasso K, Martinussen N, et al. Prostate cancer in Denmark 1978-2009--trends in incidence and mortality. Acta Oncol. 2013; 52(4): 831–836.
  41. Tatara T, Miazga W, Świtalski J, et al. Assessment of the effectiveness of clinical PSA concentration measurements in early prostate cancer detection. Nowotwory. Journal of Oncology. 2022; 72(3): 167–173.
  42. Hugosson J, Carlsson S. Overdetection in screening for prostate cancer. Curr Opin Urol. 2014; 24(3): 256–263.
  43. Prajsner A, Chudek J, Szybalska A, et al. PolSenior Study Group. Socioeconomic determinants of prostate-specific antigen testing and estimation of the prevalence of undiagnosed prostate cancer in an elderly Polish population based on the PolSenior study. Arch Med Sci. 2016; 12(5): 1028–1035.
  45. Lawler M, Davies L, Oberst S, et al. European Groundshot—addressing Europe's cancer research challenges: a Lancet Oncology Commission. Lancet Oncol. 2023; 24(1): e11–e56.

Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory